Biotech Hot Stock Intra-Cellular Therapies: The Next Takeover Target and Buyout Candidate for 2020?
Biotech experts are used to the never-ending merger and aquisition rumors in the news. Most of them are totally unrealistic and often lead to great disappointment and massive losses for private investors. One of the hottest biotech takeover candidate is the American company Intra-Cellular Therapies. This article highlights the fact that Intra-Cellular Therapies might be one of the next candidates for a buyout in biotech industry and explains why the current stock price offers the opportunity of a great premium.
It should be part of everyone’s investing plan to take advantage of rare opportunities. The small US biotech company Intra-Cellular Therapies clearly is such a rare opportunity. The Americans are specialized in the development of innovative medicines for the treatment of neuropsychiatric and neurological disorders, a global billion-dollar market.
In December 2019, Intra-Cellular Therapies has received the FDA’s go-ahead to market its first drug named Caplyta (Lumateperone) in the United States. Caplyta is indicated for the treatment of adults with schizophrenia, a serious mental disorder with a high unmet medical need. Caplyta is characterized by a highly innovative mechanism of action and a promising safety profile and has the potential to reach blockbuster status, meaning it can achieve yearly global sales of more than $1 billion in the next few years.
After Intra-Cellular’s announcement of receiving the FDA approval for Caplyta in December 2019, the company’s stock skyrocketed from $12.44 to $38.49 within just 4 days (+309.4%!). As a result of the coronavirus crisis, the share price came down again to $16.76 until the end of April, offering a great opportunity for an investment.
Stock Price Intra-Cellular Therapies
But Caplyta for Schizophrenia is not yet the full story. In fact, the company has to offer much more (please see pipeline overview below). Caplyta is also being investigated in late-stage clinical trials for the treatment of bipolar depression and behavioral disturbances associated with dementia including Alzheimer’s Disease, highly lucrative markets as well.
With the so-called PDE inhibitors, the biotech also follows a new treatment approach for Parkinson’s Disease and Heart failure. As you might have realized, Intra-Cellular Therapeutics is not just focusing on the small niche markets. No, they are going all-in and develop drugs for most profitable therapeutic areas with a high unmet medical need.
If only one of these studies turns out to be positive, the share will definitely go through the roof. It is exactly this combination of outstanding prospects and a very moderate market cap of only $1.37 billion which makes Intra-Cellular Therapies one of the most promising takeover candidate in biotech industry.
Intra-Cellular Therapies: Pipeline Overview
You can find lots of great articles about the best biotech stocks to buy now as well an update on the Biotech Investments Model Portfolio in our free monthly Biotech Investments MAGAZINE. Do you want to subscribe?
- Just send an email with “MAGAZINE” to email@example.com
- You will receive it immediately by email
- Enjoy reading, it’s entirely free!